You are here: Industry Insights > SCD

News List

Crizanlizumab Receives FDA Breakthrough Therapy Designation americanpharmaceuticalreview
January 09, 2019
Novartis announced the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of .....
New Parkinson's disease drug target revealed through study of fatty acids worldpharmanews
December 06, 2018
Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the brain's lipids as a potentially critical contributor to this diseas
FDA agrees accelerated approval pathway for GBT’s voxelotor pharmaceutical-technology
December 05, 2018
The US Food and Drug Administration (FDA) has granted San Francisco-based Global Blood Therapeutics (GBT)’s sickle cell disease (SCD) therapy voxelotor an accelerated approval under the subpart H pathway.
Novartis Announces New Crizanlizumab Data Analysis in Sickle Cell Disease americanpharmaceuticalreview
December 04, 2018
New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated.....
SCD Patients to Greet the First New Drug, the Gene Therapy to Hold Up Their Future en-cphi.cn
July 28, 2017
The Endari of Emmaus Life Sciences, Inc. was approved the marketing by FDA last week for symptom control of SCD (sickle cell disease) patients aged above 5. It is an oral L-glutamine and the first drug that can be used for pediatric patients with SCD.

Previous page 1 2 Next page